✦ The Abel Era's First DealsNarrow moat
Berkshire Hathaway (BRK.B) — the future bets
The succession worry was paralysis; the answer was OxyChem and a homebuilder — the old playbook, run at a new tempo.
The market's great worry about Berkshire-after-Buffett was paralysis; the first year answered with transactions. OxyChem — Occidental's petrochemical unit, a cash-generative commodity-chemicals franchise — was agreed for $9.7 billion in October 2025 and closed in January, the biggest purchase since Alleghany in 20221. Taylor Morrison, a top-five American homebuilder, was agreed on 31 May at $72.50 a share in cash, about $6.8 billion, and closed on 24 July.2 With $11.6 billion of net stock buying in the first half on top, Abel's first stretch committed more capital than Buffett's last two years combined.34
The shape of the buying says as much as the size: whole operating companies in unglamorous industries — chemicals, housing — bought at sensible multiples for their cash flows, not their stories. That is the old playbook run at a new tempo, and it quietly rebuts the fear that permanence and deal flow died with the founder's rolodex. The watch items are discipline's twin failure modes: a hurried big deal that overpays to prove the machine still works, or a return to stillness once the opening statement is made. Deal cadence and prices paid — both visible in every quarterly filing — are the scoreboard.
Widening by transaction: two whole companies and nearly $20B of net stock buying in the first stretch — more deployment than the final Buffett years. The test is that the cadence reflects opportunity, not a need to prove the machine still works.
The first two deals were a chemical maker and a homebuilder, both cyclical. Their earnings through a downturn will judge the price.
Source: Berkshire Form 10-Q, quarter ended 30 June 2026 ↗- ReportedOxyChem — Occidental's petrochemical unit, a cash-generative commodity-chemicals franchise — was agreed for $9.7 billion in October 2025 and closed in January, the biggest purchase since Alleghany in 2022.CNBC — Berkshire to buy Occidental's OxyChem for $9.7B in cash (announced Oct 2, 2025) — the biggest deal since Alleghany (2022); completed Jan 2, 2026 — Oct 2025 – Jan 2026 · publ. Oct 2, 2025 · source ↗
- ReportedTaylor Morrison, a top-five American homebuilder, was agreed on 31 May at $72.50 a share in cash, about $6.8 billion, and closed on 24 July.Berkshire Hathaway Form 10-Q, quarter ended 30 June 2026 - after-tax earnings (underwriting $1,731M vs $1,992M, insurance investment income $3,059M vs $3,367M, BNSF $1,558M vs $1,466M, BHE $891M vs $702M, manufacturing, service and retailing $4,470M vs $3,601M, investment gains $12,684M, net earnings $25,667M); GEICO pre-tax underwriting $994M vs $1,821M, combined ratio 91.2% vs 83.5%; Reinsurance $913M vs $650M; float $177.5B; insurance and other cash and Treasury Bills net $359.2B; consolidated cash $35,096M + $324,905M + $5,513M; equity securities $323.8B; H1 purchases of equities $39.4B and sales $27.8B; acquisitions of businesses net of cash $9.7B; $4.8B of treasury stock acquired in H1, most in Q2; OxyChem about $9.4B on 2 January; Taylor Morrison agreed 31 May at $72.50 a share, about $6.8B, closed 24 July; notes payable of insurance and other $43.3B; shareholders' equity $747.9B; BNSF revenue $6,601M vs $5,769M, fuel $1,173M vs $698M; BHE revenue $6,735M vs $6,418M; investment income down 9.1% on lower interest rates — Q2 2026 · publ. August 2026 · source ↗
- ReportedWith $11.6 billion of net stock buying in the first half on top, Abel's first stretch committed more capital than Buffett's last two years combined.Berkshire Hathaway Form 10-Q, quarter ended 30 June 2026 - after-tax earnings (underwriting $1,731M vs $1,992M, insurance investment income $3,059M vs $3,367M, BNSF $1,558M vs $1,466M, BHE $891M vs $702M, manufacturing, service and retailing $4,470M vs $3,601M, investment gains $12,684M, net earnings $25,667M); GEICO pre-tax underwriting $994M vs $1,821M, combined ratio 91.2% vs 83.5%; Reinsurance $913M vs $650M; float $177.5B; insurance and other cash and Treasury Bills net $359.2B; consolidated cash $35,096M + $324,905M + $5,513M; equity securities $323.8B; H1 purchases of equities $39.4B and sales $27.8B; acquisitions of businesses net of cash $9.7B; $4.8B of treasury stock acquired in H1, most in Q2; OxyChem about $9.4B on 2 January; Taylor Morrison agreed 31 May at $72.50 a share, about $6.8B, closed 24 July; notes payable of insurance and other $43.3B; shareholders' equity $747.9B; BNSF revenue $6,601M vs $5,769M, fuel $1,173M vs $698M; BHE revenue $6,735M vs $6,418M; investment income down 9.1% on lower interest rates — Q2 2026 · publ. August 2026 · source ↗
- ReportedWith $11.6 billion of net stock buying in the first half on top, Abel's first stretch committed more capital than Buffett's last two years combined.The Motley Fool — Abel's first-year deployment: OxyChem ($9.7B) + Taylor Morrison homebuilder ($6.8B, Jun 2026) ≈ $16.2B of whole companies in H1 2026; ~$19.8B of net stock buying per 13F; cash ~$344B, off the record — H1 2026 · publ. Aug 3, 2026 · source ↗
- Berkshire Hathaway Form 10-K filings — Business & Risk Factors (SEC EDGAR)
- OxyChem deal (CNBC, Oct 2025)
- OxyChem completion (Occidental)